Markets:

Overview

News

Currencies

International

Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

111.03 -2.52 (-2.22%)

Streaming Delayed Price Updated: 10:25 AM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 4 5 Next >

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗

May 18, 2026

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗

May 18, 2026

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.

Via The Motley Fool

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗

May 18, 2026

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

Via The Motley Fool

Topics ETFs Regulatory Compliance

What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗

May 18, 2026

Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Via The Motley Fool

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗

May 18, 2026

Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.

Via The Motley Fool

Topics Regulatory Compliance

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.

Via The Motley Fool

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗

May 17, 2026

Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗

May 17, 2026

Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.

Via The Motley Fool

Topics Regulatory Compliance

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗

May 17, 2026

This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.

Via The Motley Fool

Topics Regulatory Compliance

Abivax Announces Results of its May 11, 2026 Annual General Meeting

May 11, 2026

From Abivax

Via GlobeNewswire

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

May 05, 2026

From Abivax

Via GlobeNewswire

Abivax to Present Data on Obefazimod at Digestive Disease Week®

April 22, 2026

From Abivax

Via GlobeNewswire

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

April 20, 2026

From Abivax

Via GlobeNewswire

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy? ↗

April 07, 2026

We'll soon know more about the drugmaker's long-term prospects.

Via The Motley Fool

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

April 01, 2026

From Abivax

Via GlobeNewswire

2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗

March 26, 2026

They could make important breakthroughs in their target markets.

Via The Motley Fool

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

March 23, 2026

From Abivax

Via GlobeNewswire

Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity

March 23, 2026

As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook,...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

2 Healthcare Stocks to Buy Before They Get Bought Out ↗

March 20, 2026

Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets.

Via The Motley Fool

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗

March 16, 2026

Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.

Via The Motley Fool

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗

March 16, 2026

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Via The Motley Fool

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Via The Motley Fool

Topics Regulatory Compliance

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗

March 16, 2026

Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.

Via The Motley Fool

Topics Regulatory Compliance

What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗

March 16, 2026

Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗

March 16, 2026

This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.

Via The Motley Fool

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗

March 16, 2026

Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.

Via The Motley Fool

Topics Regulatory Compliance

This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗

March 16, 2026

Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year ↗

March 10, 2026

Is there any upside left for this rising biotech?

Via The Motley Fool

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.